December 2018 - Clinical trial profile - locations, conditions, companies -

Clinical Trials for Relistor

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00804141	Study Evaluating Long-Term Safety Of MOA-728 In Subjects With Opioid-Induced Constipation	Completed	Pfizer	Phase 3	This is a one-year study to evaluate the long-term safety and tolerability of the subcutaneous (just under the skin) injection form of MOA-728 for the treatment of opioid-induced constipation in subjects with nonmalignant pain. The study consists of a 2 week screening period, a 48 week open-label treatment period and a 2 week follow-up period. Subjects will need to agree to self-administer subcutaneous injections, complete daily diaries, and check-in via a daily telephone call during that year-long period.
NCT00804141	Study Evaluating Long-Term Safety Of MOA-728 In Subjects With Opioid-Induced Constipation	Completed	Valeant Pharmaceuticals International, Inc.	Phase 3	This is a one-year study to evaluate the long-term safety and tolerability of the subcutaneous (just under the skin) injection form of MOA-728 for the treatment of opioid-induced constipation in subjects with nonmalignant pain. The study consists of a 2 week screening period, a 48 week open-label treatment period and a 2 week follow-up period. Subjects will need to agree to self-administer subcutaneous injections, complete daily diaries, and check-in via a daily telephone call during that year-long period.
NCT00949377	Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department?	Withdrawn	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 4	The investigators want to prove that people WITHOUT advanced cancer who are taking opioid medications (for problems like back pain) can receive methylnaltrexone (MNTX) safely. Since the FDA has only approved MNTX for advanced cancer patients, the investigators' research is investigating how MNTX can work for NON-cancer patients. This research is being conducted to prove that MNTX can work for non-cancer patients with opioid related constipation.
NCT00949377	Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department?	Withdrawn	Beth Israel Medical Center	Phase 4	The investigators want to prove that people WITHOUT advanced cancer who are taking opioid medications (for problems like back pain) can receive methylnaltrexone (MNTX) safely. Since the FDA has only approved MNTX for advanced cancer patients, the investigators' research is investigating how MNTX can work for NON-cancer patients. This research is being conducted to prove that MNTX can work for non-cancer patients with opioid related constipation.
NCT01004393	Methylnaltrexone for Opioid-induced Constipation in Cancer Patients	Completed	University of Vermont	Phase 2	The purpose of this study is to evaluate the efficacy of methylnaltrexone in relieving opioid-induced constipation in cancer patients at various stages of disease.
Trial ID	Title	Status	Sponsor	Phase	Summary